Northwest Biotherapeutics makes changes to management team
Linda Powers becomes chief executive
Linda Powers, who has been chairman since May 2007, has become chief executive, while Dr Anthony Maida, a senior executive in the field of cancer immune therapies, is joining the company as chief operating officer on 20 June.
Dr Alton Boynton, the scientific founder of NWBT and chief executive since May 2007, is returning to the position of chief scientific officer.
Les Goldman, a former partner at US law firm Skadden, Arps, specialising in advanced technology commercialisation, has been appointed as senior vice president, business development. Dr Marnix Bosch will continue in his role as chief technology officer.
You may also like
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical
Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit
As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio